LG Corp.

Since its inception in 2003 as a holding company, LG has gone on to broaden its portfolio in electronics, chemicals, telecommunications, and service sectors while strengthening its expertise in each field.

26 Chemicals
- LG Chem
- LG Hausys
- LG Household & Healthcare etc.

17 Electronics
- LG Electronics
- LG Display
- LG Innotek etc.

29 Telecommunication & service
- LG U+
- LG CNS
- LG International Serveone etc.
Over 35 years of Experience in Biopharmaceutical Business

- **1981** Established as Biopharmaceutical Research Department
- **1990** In-house development and launch of 1st biopharmaceutical product (INTERMAX™-γ) in Korea
- **1996** 1st WHO prequalification of Hepatitis B vaccine (EUVAX B®) in Korea
- **2003** 1st NCE approved by US FDA (FACTIVE®) in Korea
- **2007** 1st biologics approved by US FDA & EMEA (VALTROPIN®) in Korea
- **2012** In-house development and launch of 1st diabetic drug (ZEMIGLO®) in Korea
  - WHO prequalification of pentavalent vaccine (EUFORVAC- HIB™)
- **2016** WHO prequalified fully liquid pentavalent vaccine (EUPENTA™)
- **2018** 1st biosimilar (Eucept®) approved by PMDA in Japan

Manufacturing Facility

- **Headquarters**
  - Business Unit
  - Clinical Dev.
  - Regulatory Affairs
- **Osong Plant**
  - Vaccine (WHO PQ)
  - Production
  - AID Production
  - Future Product
- **Onsan Plant**
  - Chemical API Production
- **Ik-san Plant**
  - HepB Vaccine (WHO PQ)
  - Biological Drug Substance Production
We have secured competitive edge in the pharmaceutical market, based on our superior technologies and R&D capabilities.

Based on our superior biotechnology and R&D capabilities accumulated since 1980s, we have been successful in developing a variety of original products including Korea’s first growth hormone for children, new drugs for diabetes, etc. At the same time, we have continuously expanded our competitive edge through cooperation with global pharmaceutical companies.
# Zemiglo® Tablet

The optimized DPP-4 inhibitor having potent efficacy, reliable safety and better compliance benefits.

### COMPOSITION

Each tablet contains 68.9mg gemigliptin tartrate sesquihydrate equivalent to 50mg of gemigliptin.

### INDICATION

As monotherapy or in combination with:
- Metformin as initial therapy in treatment naive patients inadequately controlled by diet and exercise alone.
- Metformin in patients with inadequate glycemic control with the maximal tolerated dose of metformin alone.
- Metformin and sulphonylurea in patients with inadequate glycemic control with the maximal tolerated dose of metformin and sulphonylurea dual therapy.

### DOSAGE & ADMINISTRATION

The recommended daily dose of Zemiglo® is 50mg. Zemiglo® can be taken with or without food. No dosage adjustment is required for patients with renal impairment and mild or moderate hepatic impairment.

### HOW SUPPLIED

Zemiglo® is available as clear blisters (PVC/PVDC and aluminum). Pack of 28 or 56 film-coated tablets in unit dose blisters.

### STORAGE CONDITION

Store at room temperature (1~30℃) in tight container.

### SHELF LIFE

48 months

---

# Zemimet® SR Tablet

Once daily DPP-IV inhibitor and Metformin SR combination product.

### COMPOSITION

Four-dosage tablets contain active ingredients respectively:
- **25/500mg**: gemigliptin 25mg and metformin 500mg
- **50/1000mg**: gemigliptin 50mg and metformin 1000mg
- **50/500mg**: gemigliptin 50mg and metformin 500mg
- **25/1000mg**: gemigliptin 25mg and metformin 1000mg

### INDICATION

Zemimet® SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Zemimet® SR can be administered:

1) As initial therapy for treatment naive patients with inadequate glycemic control by diet and exercise alone.
2) In patients with inadequate glycemic control with the maximal tolerated dose of metformin alone.
3) In combination with sulphonylurea in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.
4) In patients already receiving an identical combination of gemigliptin and metformin as separate tablets.

### DOSAGE & ADMINISTRATION

The recommended dose of Zemimet®SR is once daily. Zemimet®SR should be generally administered once daily with a meal in the evening. The maximum recommended daily dose is 50mg gemigliptin and 2000mg metformin extended-release.

### HOW SUPPLIED

- **50/500mg**: Zemimet® SR 50/500mg is oval shaped, orange colored, film-coated tablet
- **25/500mg**: Zemimet® SR 25/500mg is oval shaped, yellow colored, film-coated tablet
- **50/1000mg**: Zemimet® SR 50/1000mg is oblong shaped, brown colored, film-coated tablet
- **25/1000mg**: Zemimet® SR 25/1000mg is oblong shaped, yellowish-brown colored, film-coated tablet

Opaque blisters (PVC/PVDC and aluminum). A pack of 28 or 56 film-coated tablets in unit dose blisters.

### STORAGE CONDITION

Store at room temperature (1~30℃) in tight container.

### SHELF LIFE

36 months
**Zemiro® Tablet**

**DOSAGE & ADMINISTRATION**

Zemiro® is available as three dosages: 50/20 mg, 50/10 mg, and 50/5 mg and taken once daily.

**COMPOSITION**

Zemiro® is available as three doses which contain gemigliptin tartrate androsuvasatin calcium.

- 50/20 mg: gemigliptin 50 mg/rosuvastatin 20 mg
- 50/10 mg: gemigliptin 50 mg/rosuvastatin 10 mg
- 50/5 mg: gemigliptin 50 mg/rosuvastatin 5 mg

**INDICATION**

Zemiro® is a combination of gemigliptin and rosuvastatin indicated for patients who require administration of both products.

---

**Rovatitan® Tablet**

**INDICATION**

ROVATITAN® is indicated for the treatment of patients who must administer both rosuvastatin and valsartan.

**DOSAGE & ADMINISTRATION**

Once-daily Dosage must be individualized on the basis of both effectiveness and tolerance of valsartan and rosuvastatin.

**HOW SUPPLIED**

- 5/80 mg: light-orange colored, circular-shaped, film-coated tablet
- 5/160 mg: light-orange colored, oval-shaped, film-coated tablet
- 10/80 mg: pink colored, circular film-coated tablet
- 10/160 mg: pink colored, oval film-coated tablet
- 20/80 mg: brown colored, circular film-coated tablet
- 20/160 mg: brown colored, oval film-coated tablet

**COMPOSITION**

Six-dosage tablets contain active ingredients respectively:

- 5/80 mg: rosuvastatin 5mg and valsartan 80mg
- 5/160 mg: rosuvastatin 5mg and valsartan 160mg
- 10/80 mg: rosuvastatin 10mg and valsartan 80mg
- 10/160 mg: rosuvastatin 10mg and valsartan 160mg
- 20/80 mg: rosuvastatin 20mg and valsartan 80mg
- 20/160 mg: rosuvastatin 20mg and valsartan 160mg

**STORAGE CONDITION**

Store at room temperature (1-30°C) in light-resistant tight container.

**SHELF LIFE**

36 months.

---

**Factive® Tablet / Injection**

**INDICATION**

Factive® is a dual targeting quinolone with broad spectrum marketed more than 20 countries including US. Intravenous formulation has been approved in Korea.

**COMPOSITION**

- Factive® Tablet: Each tablet contains gemifloxacin mesylate equivalent to 320mg of gemifloxacin
- Factive® Injection: Each vial contains gemifloxacin mesylate equivalent to 200mg of gemifloxacin

**STORAGE CONDITION**

Store at room temperature (1-30°C) in light-resistant tight container.

**SHELF LIFE**

- 320 mg (oral): 48 months
- 200 mg (IV): 36 months

---

**Zemiglo® / Zemimet® SR / Zemiro® Tablet**

**INDICATION**

US FDA approved respiratory fluoroquinolone antibiotic, gemifloxacin.

Factive® is a dual targeting quinolone with broad spectrum marketed more than 20 countries including US. Intravenous formulation has been approved in Korea.

**COMPOSITION**

- Factive® Tablet: Each tablet contains gemifloxacin mesylate equivalent to 320mg of gemifloxacin
- Factive® Injection: Each vial contains gemifloxacin mesylate equivalent to 200mg of gemifloxacin

**STORAGE CONDITION**

- Factive® tablet: white to off-white, oval, film-coated tablet
- Factive® injection: White to light brown lyophilized powder in a brown vial

**SHELF LIFE**

- Factive® tablet: 48 months
- Factive® injection: 36 months

---

**Factive® Tablet / Injection**

**INDICATION**

Factive® is a dual targeting quinolone with broad spectrum marketed more than 20 countries including US. Intravenous formulation has been approved in Korea.

**COMPOSITION**

- Factive® Tablet: Each tablet contains gemifloxacin mesylate equivalent to 320mg of gemifloxacin
- Factive® Injection: Each vial contains gemifloxacin mesylate equivalent to 200mg of gemifloxacin

**STORAGE CONDITION**

- Factive® tablet: white to off-white, oval, film-coated tablet
- Factive® injection: White to light brown lyophilized powder in a brown vial

**SHELF LIFE**

- Factive® tablet: 48 months
- Factive® injection: 36 months
Espogen® / Epotiv® Erythropoietin Injection

**Biologics**

Free from human serum albumin, manufactured by bioreactor process.

Espogen® is a recombinant human erythropoietin for the treatment of anemia induced by chronic renal failure in patients with or without dialysis. It is manufactured by bioreactor process which does not use animal-derived material, is free from human serum albumin.

- Recombinant human erythropoietin using CHO cells
- Manufactured by bioreactor process capable of covering high capacity
- Devoid of additives derived from animal origin in the manufacture process
- Safe and effective treatment for renal anemia associated with chronic renal failure (CRF)
- Newly developed for global market

**COMPOSITION**
- Each pre-filled syringe contains 1,000, 2,000, 3,000, 4,000, 6,000, 8,000 or 10,000 IU of mEPO
- Each vial contains 4,000, 10,000 or 20,000 IU of mEPO

**INDICATION**
Treatment of anemia of chronic renal failure (CRF) patients

**DOSAGE & ADMINISTRATION**
Initial dose: Administer 50 IU/kg, 3 times a week or 150 IU/kg once a week by SC or IV injection over 1~2 minutes

Maintenance dose: If 30~35% of Hct level is achieved, administer 20~50 IU/kg, 2~3 times a week, in any case, maximum dose should not exceed 200IU/kg in a single day, 3 times per week.

**HOW SUPPLIED**
Vial: 10 vials / box
PFS: 6 syringes / box

**STORAGE CONDITION**
Store in hermetic container at 2-8℃. Do not freeze or shake.

**Shelf Life**
24 months
**Eutropin® / Eutropin® Pen** Somatropin Injection

LG Chem is committed to leadership and innovation in GHD therapy.

- Manufactured using LG Chem’s advanced technology
  - Drug substance approved by US FDA
  - Uniquely produced in yeast (Saccharomyces cerevisiae)
  - GRAS by FDA hence, non-pathogenic and non-pyrogenic
  - Proven quality: Proven efficacy and safety, 20 years of patient experience

**Eutropin® Injection 4 IU**

**COMPOSITION**
Each vial contains 4 IU of recombinant human growth hormone

**INDICATION**
Short stature due to an inadequate secretion of endogenous growth hormone in prepubertal children (Pediatric Growth Hormone Deficiency, PGHD)

**DOSAGE & ADMINISTRATION**
1. PGHD: 0.5~0.6IU/kg/week or 12IU/m² (body surface area)/week, 3 or 6 times per week, subcutaneously.
2. TS: 0.15IU/kg/day, subcutaneously.
3. SGA: 0.48mg/kg/week, 6 to 7 times per week, subcutaneously.
4. ISS: 0.37mg/kg/week, 6 times per week, subcutaneously.
5. Replacement therapy in adults with GH deficiency of either childhood- or adult-onset etiology.

**HOW SUPPLIED**
4 IU/vial x 1, 5, 10 vials/pack (with solvent)
15 IU/vial x 1 vial/pack (with solvent)
36 IU/pen/pack

**STORAGE CONDITION**
Store in hermetic container at 2~8℃.

**SHELF LIFE**
4 IU: 36 months
15 IU: 36 months
36 IU: 18 months

---

**Eutropin® Pen Injection 36 IU**

**COMPOSITION**
Each pen contains 36 IU of recombinant human growth hormone

**INDICATION**
Short stature due to an inadequate secretion of endogenous growth hormone in prepubertal children (Pediatric Growth Hormone Deficiency, PGHD)

**DOSAGE & ADMINISTRATION**
1. PGHD: 0.5~0.6IU/kg/week or 12IU/m² (body surface area) /week, 3 or 6 times per week, subcutaneously.
2. TS: 0.15IU/kg/day, subcutaneously.
3. CRI: 0.15IU/kg/day, subcutaneously.
4. SGA: 0.48mg/kg/week, 6 to 7 times per week, subcutaneously.
5. ISS: 0.37mg/kg/week, 6 times per week, subcutaneously.
6. Replacement therapy in adult GHD: A starting dose of 0.125IU/kg/week may be increased to a maximum 0.25IU/kg/week, 6 to 7 times per week.

**HOW SUPPLIED**
4 IU/vial x 1, 5, 10 vials/pack (with solvent)
15 IU/vial x 1 vial/pack (with solvent)
36 IU/pen/pack

**STORAGE CONDITION**
Store in hermetic container at 2~8℃.

**SHELF LIFE**
4 IU: 36 months
15 IU: 36 months
36 IU: 18 months

---

**Declage® Somatropin Injection**

Once weekly hGH product for AGHD (Adult Growth Hormone Deficiency) patients

**COMPOSITION**
Each vial contains 24mg of recombinant human growth hormone

**INDICATION**
Replacement therapy in adults with GH deficiency of either childhood- or adult-onset etiology

**DOSAGE & ADMINISTRATION**
The recommended dosage at the start of therapy is 2mg/week. The dose may be increased according to individual patient requirements to a maximum of 4mg/week

**HOW SUPPLIED**
24mg/vial with accompanying solvent in a pre-filled syringe/unit

**STORAGE CONDITION**
Store at 2~8℃. Do not freeze.

**SHELF LIFE**
36 months
Hyruan® Series  Viscosupplementation for osteoarthritis treatment

Since early 1990s, LG’s sodium hyaluronate is microbiologically fermented using Streptococcus zoaeipidicus with high purity and consistency. To pursue the global standard, our hyaluronate gained Certificate of Suitability from European Directorate for the Quality of Medicines (EDQM).

Treatment of degenerative joint diseases
Hyaluronic acid is a natural polysaccharide which moisturizes and lubricates the body’s soft tissue. It protects injured chondrocyte by building proteoglycan aggregates and suppressing degenerative change of cartilage. It is the major macromolecule species in synovial fluid and is responsible for the fluid’s viscoelastic properties.

Hyruan ONE®
Novel single injection with cross-linked HA

COMPOSITION
Each mL contains 20mg of cross-linked sodium hyaluronate

INDICATION
For use as a symptomatic treatment for osteoarthritis of the knee

DOSAGE & ADMINISTRATION
3.0mL at once by intra-articular injection

HOW SUPPLIED
3.0mL in a prefilled syringe/box

STORAGE CONDITION
Store in hermetic container at 1-30°C. Protect from light.

SHELF LIFE
24 months.

Hyruan Plus®
Three-injection with high molecular weight HA

COMPOSITION
Each mL contains 10mg of sodium hyaluronate

INDICATION
Osteoarthritis of the knees and periarthritis of the shoulder

DOSAGE & ADMINISTRATION
2.0mL, once a week for 3 weeks by intra-articular injection

HOW SUPPLIED
2.0mL in a prefilled syringe X 1, 3/box

STORAGE CONDITION
Store in hermetic container at 2-25°C. Protect from light.

SHELF LIFE
24 months.

Hyruan®
Five-injection with low molecular weight HA

COMPOSITION
Each mL contains 10mg of sodium hyaluronate

INDICATION
Osteoarthritis of the knees and periarthritis of the shoulder

DOSAGE & ADMINISTRATION
2.5mL, once a week for 5 weeks by intra-articular injection

HOW SUPPLIED
2.5mL in a prefilled syringe X 1, 5/box

STORAGE CONDITION
Store in hermetic container at 2-8°C, in the refrigerator. Protect from light.

SHELF LIFE
36 months.

Protescal™ Post-operative anti-adhesive agent

It is a biodegradable and absorbable adhesion barrier composed of sodium hyaluronate, carboxymethylcellulose (CMC) and sodium alginate. It effectively prevents the formation of adhesions between tissues after intrauterine surgery and degrades safely in our body.

DESCRIPTION
This is a viscous solution type product presented in a prefilled syringe filled with 1.5mL, 5.0mL of colorless, clear and viscous liquid.

INDICATION
It is mainly used after the intrauterine surgery to reduce the adhesion of the surrounding tissues as a dressing for deep cavity wounds.

HOW SUPPLIED
1.5mL, 5.0mL in a prefilled syringe/box

STORAGE CONDITION
2-25°C, Free from light, in a hermetic container.

SHELF LIFE
24 months.

Hyal® Series  Injection for ophthalmic surgery

Hyal Plus®

COMPOSITION
Each mL contains 15mg of sodium hyaluronate

INDICATION
Used in surgical interventions involving the anterior chamber, such as cataracts (crystalline lens transplants), corneal transplants and glaucoma operations

DOSAGE & ADMINISTRATION
Injection volume is adjusted according to the type of eye surgery:
- Cataract Surgery and Intraocular Lens Implantation
- Keratoplasty
- Glaucoma Filtration Surgery

HOW SUPPLIED
0.85mL in a prefilled syringe/box

STORAGE CONDITION
Store in hermetic container at 2-8°C, in the refrigerator. Protect from light.

SHELF LIFE
36 months.

Hyal 2000®

COMPOSITION
Each mL contains 10mg of sodium hyaluronate

INDICATION
Used in surgical interventions involving the anterior chamber, such as cataracts (crystalline lens transplants), corneal transplants and glaucoma operations

DOSAGE & ADMINISTRATION
Injection volume is adjusted according to the type of eye surgery:
- Cataract Surgery and Intraocular Lens Implantation
- Keratoplasty
- Glaucoma Filtration Surgery

HOW SUPPLIED
0.85mL in a prefilled syringe/box

STORAGE CONDITION
Store in hermetic container at 2-8°C, in the refrigerator. Protect from light.

SHELF LIFE
36 months.

DESCRIPTION
This is a viscous solution type product presented in a prefilled syringe filled with 1.5mL, 5.0mL of colorless, clear and viscous liquid.

INDICATION
It is mainly used after the intrauterine surgery to reduce the adhesion of the surrounding tissues as a dressing for deep cavity wounds.

HOW SUPPLIED
1.5mL, 5.0mL in a prefilled syringe/box

STORAGE CONDITION
2-25°C, Free from light, in a hermetic container.

SHELF LIFE
24 months.

It is a biodegradable and absorbable adhesion barrier composed of sodium hyaluronate, carboxymethylcellulose (CMC) and sodium alginate. It effectively prevents the formation of adhesions between tissues after intrauterine surgery and degrades safely in our body.

DESCRIPTION
This is a viscous solution type product presented in a prefilled syringe filled with 1.5mL, 5.0mL of colorless, clear and viscous liquid.

INDICATION
It is mainly used after the intrauterine surgery to reduce the adhesion of the surrounding tissues as a dressing for deep cavity wounds.

HOW SUPPLIED
1.5mL, 5.0mL in a prefilled syringe/box

STORAGE CONDITION
2-25°C, Free from light, in a hermetic container.

SHELF LIFE
24 months.

It is a biodegradable and absorbable adhesion barrier composed of sodium hyaluronate, carboxymethylcellulose (CMC) and sodium alginate. It effectively prevents the formation of adhesions between tissues after intrauterine surgery and degrades safely in our body.

DESCRIPTION
This is a viscous solution type product presented in a prefilled syringe filled with 1.5mL, 5.0mL of colorless, clear and viscous liquid.

INDICATION
It is mainly used after the intrauterine surgery to reduce the adhesion of the surrounding tissues as a dressing for deep cavity wounds.

HOW SUPPLIED
1.5mL, 5.0mL in a prefilled syringe/box

STORAGE CONDITION
2-25°C, Free from light, in a hermetic container.

SHELF LIFE
24 months.

It is a biodegradable and absorbable adhesion barrier composed of sodium hyaluronate, carboxymethylcellulose (CMC) and sodium alginate. It effectively prevents the formation of adhesions between tissues after intrauterine surgery and degrades safely in our body.

DESCRIPTION
This is a viscous solution type product presented in a prefilled syringe filled with 1.5mL, 5.0mL of colorless, clear and viscous liquid.

INDICATION
It is mainly used after the intrauterine surgery to reduce the adhesion of the surrounding tissues as a dressing for deep cavity wounds.

HOW SUPPLIED
1.5mL, 5.0mL in a prefilled syringe/box

STORAGE CONDITION
2-25°C, Free from light, in a hermetic container.

SHELF LIFE
24 months.
**Tissue augmentation and wrinkle correction**

Based on the original technology for manufacturing high-quality sodium hyaluronate, LG Chem developed a biomaterial for tissue augmentation using the cross-linked sodium hyaluronate. It is injected into the facial skin layer in the face using separate needles supplied with YVOIRE® series use HICE (High Concentration Equalized) crosslinking technology which effectively stabilizes high concentration, high molecular weight HA.

### YVOIRE® classic s

**COMPOSITION**
Cross-linked sodium hyaluronate 22mg/mL (2.2%)

**INDICATION**
Facial tissue augmentation by injection into areas in which restoration is required. Typically used for treatment of facial wrinkles and folds, and also for augmentation of lips.

**HOW SUPPLIED**
1.0mL in a prefilled syringe/box with 27G & 30G needles

**STORAGE CONDITION**
2~25℃ free from light, in a hermetic container.

**SHELF LIFE**
24 months

### YVOIRE® classic plus

**COMPOSITION**
Cross-linked sodium hyaluronate 20mg/mL (2.0%)
Lidocaine hydrochloride 0.3%

**INDICATION**
Facial tissue augmentation by injection into areas in which restoration is required. Typically used for treatment of facial wrinkles and folds, and also for augmentation of lips. The addition of lidocaine provides a pain relieving effect during treatment.

**HOW SUPPLIED**
1.0mL in a prefilled syringe/box with 27G & 30G needles

**STORAGE CONDITION**
2~25℃ free from light, in a hermetic container.

**SHELF LIFE**
24 months

### YVOIRE® volume s

**COMPOSITION**
Cross-linked sodium hyaluronate 22mg/mL (2.2%)

**INDICATION**
Facial tissue augmentation by injection into areas in which restoration is required. Typically used for treatment of severe facial wrinkles and folds, and also for augmentation of lips.

**HOW SUPPLIED**
1.0mL in a prefilled syringe/box with two 27G needles

**STORAGE CONDITION**
2~25℃ free from light, in a hermetic container.

**SHELF LIFE**
24 months

### YVOIRE® volume plus

**COMPOSITION**
Cross-linked sodium hyaluronate 20mg/mL (2.0%)
Lidocaine hydrochloride 0.3%

**INDICATION**
Facial tissue augmentation by injection into areas in which restoration is required. Typically used for treatment of severe facial wrinkles and folds, and also for augmentation of lips. The addition of lidocaine provides a pain relieving effect during treatment.

**HOW SUPPLIED**
1.0mL in a prefilled syringe/box with two 27G needles

**STORAGE CONDITION**
2~25℃ free from light, in a hermetic container.

**SHELF LIFE**
24 months

### YVOIRE® contour s

**COMPOSITION**
Cross-linked sodium hyaluronate 22mg/mL (2.2%)

**INDICATION**
Facial tissue augmentation typically used for treatment of extreme facial wrinkles and folds, and also replacement of volume defects, facial lipoprotein and improvement of facial contour deformities by injection in the facial subcutaneous and supraperiosteal facial layers

**HOW SUPPLIED**
2.0mL in a prefilled syringe/box with 21G & 23G needles

**STORAGE CONDITION**
2~25℃ free from light, in a hermetic container.

**SHELF LIFE**
24 months

### YVOIRE® contour plus

**COMPOSITION**
Cross-linked sodium hyaluronate 20mg/mL (2.0%)
Lidocaine hydrochloride 0.3%

**INDICATION**
Temporary wrinkle improvement and recovery of volume loss by injection into the skin layer. The addition of lidocaine provides a pain relieving effect during treatment.

**HOW SUPPLIED**
1.0mL in a prefilled syringe/box with 23G cannula & 23G needle

**STORAGE CONDITION**
2~25℃ free from light, in a hermetic container.

**SHELF LIFE**
24 months

### YVOIRE® hydro

**COMPOSITION**
Sodium hyaluronate 20mg/mL (2.0%)

**INDICATION**
Temporary relief of wrinkles by injection into the skin layer around the facial wrinkle area

**HOW SUPPLIED**
1.0mL in a prefilled syringe/box with two 30G needles

**STORAGE CONDITION**
2~8℃

**SHELF LIFE**
24 months
**COMPOSITION**
Cross-linked sodium hyaluronate 20mg/mL (2.0%)  
Lidocaine hydrochloride 0.3%

**INDICATION**
Temporary wrinkle improvement and recovery of volume loss by injection into the facial skin layer. The addition of lidocaine provides a pain relieving effect during treatment.

**HOW SUPPLIED**
1.0 mL in prefilled syringe/box with two 27G needles

**STORAGE CONDITION**
2~25°C free from light, in a hermetic container.

**SHELF LIFE**
17 months.

**YVOIRE® Y-Solution™ 540**

**COMPOSITION**
Cross-linked sodium hyaluronate 20mg/mL (2.0%)  
Lidocaine hydrochloride 0.3%

**INDICATION**
Temporary wrinkle improvement and recovery of volume loss by injection into the facial skin layer. The addition of lidocaine provides a pain relieving effect during treatment.

**HOW SUPPLIED**
1.0 mL in prefilled syringe/box with two 27G needles

**STORAGE CONDITION**
2~25°C free from light, in a hermetic container.

**SHELF LIFE**
17 months.

**YVOIRE® Y-Solution™ 360**

**COMPOSITION**
Cross-linked sodium hyaluronate 12mg/mL (1.2%)  
Lidocaine hydrochloride 0.3%

**INDICATION**
Temporary wrinkle improvement and recovery of volume loss by injection into the facial skin layer. The addition of lidocaine provides a pain relieving effect during treatment.

**HOW SUPPLIED**
1.0 mL in prefilled syringe/box with two 29G needles

**STORAGE CONDITION**
2~25°C free from light, in a hermetic container.

**SHELF LIFE**
17 months.

**Follitrope®**

**Injection 75, 150, 225, 300 IU**

**COMPOSITION**
Each vial contains 75 or 150 IU of recombinant follic scopin (FSH) per vial.

**INDICATION**
Controlled ovarian hyperstimulation (COH) to induce the development of multiple follicles in medically assisted reproduction program (e.g. in vitro fertilization/embryo transfer, IVF/ET, gamete intra-fallopian transfer, GIFT, zygote intra-fallopian transfer, ZIFT, intracytoplasmic sperm injection, ICSI).

**ADMINISTRATION**
Subcutaneous or intramuscular injection.

**HOW SUPPLIED**
- Follitrope® inj. vial: 75 IU 1 vial per pack (with its accompanying solvent in vial)  
- 150 IU 1, 5 vials per pack (with its accompanying solvent in vial)
- Follitrope® inj. prefilled syringe: 75, 150, 225, 300 IU 1 prefilled syringe/pack

**STORAGE CONDITION**
Avoid freezing.

**SHELF LIFE**
36 months.

**IVF-M HP™**

**Injection 75 IU**

**COMPOSITION**
Each vial contains 75 IU of FSH and 75 IU of LH.

**INDICATION**
Female: For stimulation of the development of multiple follicles (superovulation) in women undergoing assisted reproductive techniques (ART).  
For ovulatory disorder – Ovulation induction.

**ADMINISTRATION**
Subcutaneous injection.

**HOW SUPPLIED**
- IVF-M HP™ inj. vial: 75 IU/vial X 1 vial/pack (with solvent)

**STORAGE CONDITION**
Store below 25°C in hermetic container protected from light.

**SHELF LIFE**
36 months.

**IVF-M HP™**

**Injection 75 IU**

**COMPOSITION**
Each vial contains 75 IU of FSH and 75 IU of LH.

**INDICATION**
Female: For stimulation of the development of multiple follicles (superovulation) in women undergoing assisted reproductive techniques (ART).  
For ovulatory disorder – Ovulation induction.

**ADMINISTRATION**
Subcutaneous injection.

**HOW SUPPLIED**
- IVF-M HP™ inj. vial: 75 IU/vial X 1 vial/pack (with solvent)

**STORAGE CONDITION**
Store below 25°C in hermetic container protected from light.

**SHELF LIFE**
36 months.
**IVF-M™** Injection 75,150 IU

*Infertility Treatments*

**COMPOSITION**
Each vial contains 75 or 150 IU of FSH and 75 or 150 IU of LH

**INDICATION**
- Female: For stimulation of the development of multiple follicles (superovulation) in women undergoing Assisted Reproductive Techniques (ART).
- Male: Hypogonadotropic hypogonadism

**ADMINISTRATION**
Subcutaneous or intramuscular injection

**HOW SUPPLIED**
- 75 IU/vial X 1 vial/pack (with solvent)
- 150 IU/vial X 1, 5 vials/pack (with solvent)

**STORAGE CONDITION**
Store in the light-resistant place at RT (1-30°C).

**SHELF LIFE**
36 months

---

**IVF-C™** Injection 1000, 5000 IU

*Infertility Treatments*

**COMPOSITION**
Each vial contains 1,000 or 5,000 IU of hCG

**INDICATION**
- Female: Ovulation induction in women undergoing Assisted Reproductive Techniques (ART), Anovulatory Infertility, Inadequate Luteal Phase, Habitual Abortion & Threatened abortion
- Male: Hypogonadotropic hypogonadism

**ADMINISTRATION**
Intramuscular injection

**HOW SUPPLIED**
- 1,000 IU/vial X 1 vial/pack (with solvent)
- 5,000 IU/vial X 1, 3 vials/pack (with solvent)

**STORAGE CONDITION**
Store in the light-resistant cool place (below 15°C).

**SHELF LIFE**
36 months

---

**Euvax B™** Injection

*Hep B Vaccine*

**COMPOSITION**
Each ml of Euvax B™ Inj. contains
- Active ingredient: Purified HBsAg (rDNA) 10 or 20 μg
- Adjuvant: Aluminum hydroxide gel (as Al) 0.5 mg

**INDICATION**
Immunization against infection caused by all known subtypes of hepatitis B virus

**DOSAGE & ADMINISTRATION**
- Basic immunization schedule: 0-1-6 months
- Alternate immunization schedule: 0-1-2 months

**STORAGE CONDITION**
Store at 2~8℃. Do not freeze.

**SHELF LIFE**
36 months

---

**Euhib™** Injection

*Hib Vaccine*

**COMPOSITION**
Each single dose of 0.5ml contains
- Purified capsular polysaccharide (PRP) of Hib conjugated to tetanus toxoid 30~50 μg (as PRP 10 μg)
- Lactose 10.08 mg
- Sodium chloride 0.9% (w/v)
- Water for injection q.s.

**INDICATION**
Active immunization of infants and toddlers from the age of 2 months for prevention of invasive disease caused by Haemophilus influenzae type b

**DOSAGE & ADMINISTRATION**
3 doses (1 dose = 0.5 ml) at 2, 4 and 6 months of age and a booster dose of 0.5 ml at 12~15 months of age, by intramuscular injection

**STORAGE CONDITION**
Store at 2-8°C. Do not freeze.

**SHELF LIFE**
36 months

---

**Recombinant hepatitis B vaccine suspension for injection**

**CLASS**
Monovalent Vaccine

**COMPOSITION**
Each ml of Euvax B™ Inj. contains
- Active ingredient: Purified HBsAg (rDNA) 10 or 20 μg
- Adjuvant: Aluminum hydroxide gel (as Al) 0.5 mg

**INDICATION**
Immunization against infection caused by all known subtypes of hepatitis B virus

**DOSAGE & ADMINISTRATION**
- Basic immunization schedule: 0-1-6 months
- Alternate immunization schedule: 0-1-2 months

**STORAGE CONDITION**
Store at 2~8℃. Do not freeze.

**SHELF LIFE**
36 months

---

Haemophilus influenzae type b (Hib) vaccine lyophilized powder with a diluent in pre-filled syringe for injection

**CLASS**
Monovalent Vaccine

**COMPOSITION**
Each single dose of 0.5ml contains
- Lyophilized powder: Purified capsular polysaccharide (PRP) of Hib conjugated to tetanus toxoid 30~50μg (as PRP 10μg)
- Lactose: 10.08 mg
- Diluent: Sodium chloride 0.9% (w/v)
- Water for injection: 6μl

**INDICATION**
Active immunization of infants and toddlers from the age of 2 months for prevention of invasive disease caused by Haemophilus influenzae type b

**DOSAGE & ADMINISTRATION**
3 doses (1 dose = 0.5 ml) at 2, 4 and 6 months of age and a booster dose of 0.5 ml at 12~15 months of age, by intramuscular injection

**STORAGE CONDITION**
Store at 2-8°C. Do not freeze.

**SHELF LIFE**
36 months

---

**IVF-M™** Injection is a preparation of human menopausal gonadotropin (Menotropin) extracted from the urine of postmenopausal women, which contains follicle stimulating hormone (FSH) and luteinizing hormone (LH) activity in the ratio of approximately 1.

**IVF-C™** Injection is a preparation of human chorionic gonadotropin (hCG) extracted from the urine of pregnant women.
Adsorbed Diphtheria, Tetanus, whole-cell Pertussis, Hepatitis B (r-DNA) and Hib vaccine Suspension for injection

Eupenta™ Injection

DTwP-Hep B-Hib

CLASS
Pentavalent Vaccine

COMPOSITION
Each single dose of 0.5mL contains

<table>
<thead>
<tr>
<th>Component</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diphtheria toxoid</td>
<td>15 LF</td>
</tr>
<tr>
<td>Tetanus toxoid</td>
<td>10 LF</td>
</tr>
<tr>
<td>Pertussis antigen</td>
<td>≥ 4 IU</td>
</tr>
<tr>
<td>Purified hB urgency (r-DNA)</td>
<td>10 µg</td>
</tr>
<tr>
<td>Purified capsular polysaccharide (PRP) of Hib conjugated to tetanus toxoid</td>
<td>30-50 µg (as PRP 10 µg)</td>
</tr>
</tbody>
</table>

INDICATION
Active primary immunization against diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae type b disease

DOSAGE & ADMINISTRATION
3 doses (1 dose = 0.5ml) at 6, 10 and 14 weeks of age, by intramuscular injection

STORAGE CONDITION
Store at 2~8℃. Do not freeze.

SHELF LIFE
36 months

Effective, safe and convenient
- Highly immunogenic and well tolerant to the healthy infants
- Improved compliance
- Long shelf life
- Manufactured under world-class GMP standards

This booklet contains information about products which may or may not be available in any particular country, and if applicable, may have received approval or market clearance by a governmental regulatory body for different indications and restrictions in different countries. Each country has specific laws and regulations governing the communication of medical or other information about medical products. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product which is not authorized by the laws and regulations of the country where the reader resides.